Cargando…

Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells

BACKGROUND: Gastric cancer (GC) has a poor prognosis and limited therapeutic options. As a new promising cancer therapeutic approach, chimeric antigen receptor (CAR)-T cells represent a potential GC treatment. We investigated the antitumor activity of CAR-T cells target-B7H3 in GC. METHODS: In our s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Fengqiang, Yu, Xiaomei, Ju, Ruixue, Wang, Zhanzhao, Wang, Yuhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802437/
https://www.ncbi.nlm.nih.gov/pubmed/35101032
http://dx.doi.org/10.1186/s12935-022-02471-8
Descripción
Sumario:BACKGROUND: Gastric cancer (GC) has a poor prognosis and limited therapeutic options. As a new promising cancer therapeutic approach, chimeric antigen receptor (CAR)-T cells represent a potential GC treatment. We investigated the antitumor activity of CAR-T cells target-B7H3 in GC. METHODS: In our study, expression of B7H3 was examined in GC tissues and explored the tumoricidal potential of B7H3-targeting CAR-T cells in GC. B7H3-directed CAR-T cells with a humanized antigen-recognizing domain was generated. The anti-tumor effects of this CAR-T cell were finally investigated in vitro and in vivo. RESULTS: Our results show that B7H3-directed CAR-T cells efficiently killed GC tumor cells. In addition, we found that B7H3 is correlated with tumor cell stemness, and anti-B7H3 CAR-T can simultaneously target stem cell-like GC cells to improve the treatment outcome. CONCLUSIONS: Our study indicates that B7H3 is an attractive target for GC therapy, and B7H3 has high potential for clinical application. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02471-8.